SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Public ClinicalTrials.gov record NCT02048371. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT02048371
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Sarcoma Alliance for Research through Collaboration
- Other
- Enrollment
- 131 participants
Conditions and interventions
Conditions
Interventions
- Regorafenib Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 5 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2014
- Primary completion
- Apr 30, 2022
- Completion
- Apr 30, 2022
- Last update posted
- Nov 6, 2023
2014 – 2022
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| Children's Hospital Los Angeles | Los Angeles | California | 90027 | — |
| Sarcoma Oncology Research Center | Santa Monica | California | 90403 | — |
| Stanford University | Stanford | California | 94305 | — |
| Mayo Clinic - Florida | Jacksonville | Florida | 32224 | — |
| H. Lee Moffitt | Tampa | Florida | 33612 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| Dana Farber/Partners Cancer Care | Boston | Massachusetts | 02215 | — |
| Mayo Clinic - Minnesota | Rochester | Minnesota | 55905 | — |
| Carolinas Healthcare System | Charlotte | North Carolina | 28203 | — |
| Duke University | Durham | North Carolina | 27705 | — |
| Ohio State University | Columbus | Ohio | 43202 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Vanderbilt University | Nashville | Tennessee | 37232 | — |
| Texas Children's Hospital | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02048371, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 6, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02048371 live on ClinicalTrials.gov.